Ample epidemiological evidence indicates that individuals with obesity (particularly with morbid obesity), diabetes, metabolic syndrome, hypertension and coronary heart disease have decreased levels of adiponectin, with especially low HMW adiponectin [68][108–112]. Here, ADIPOQ is linked to metabolic syndrome.